Skip to main content
Clinical Trials/NCT00869102
NCT00869102
Withdrawn
Not Applicable

Characterization of Beta Cell Failure

University Hospital Tuebingen1 site in 1 countryMay 2009
InterventionsGLP-1

Overview

Phase
Not Applicable
Intervention
GLP-1
Conditions
Diabetes
Sponsor
University Hospital Tuebingen
Locations
1
Primary Endpoint
Insulin secretion
Status
Withdrawn
Last Updated
11 years ago

Overview

Brief Summary

The purpose of this study is to characterise beta cell function in subjects who despite taking part in a diabetes prevention program (life style intervention with diet and exercise) exhibit impaired glucose tolerance and beta cell dysfunction.

Detailed Description

We have identified a subgroup of individuals with a good compliance to lifestyle intervention to prevent diabetes who lose body weight and increase insulin sensitivity, however they remain impaired glucose tolerant. These individuals show a deterioration in insulin secretory function. We will identify a highly selected group of subjects with prediabetes that displays a large defect in insulin secretory function.We will study 50 individuals who display these characteristics and 50 subjects who do not display these characteristics. Their insulin secretion capacity in response to different secretagogues (glucose, GLP-1, arginine) will be studied. We expect to detect new pathophysiologic aspects that lead to beta cell failure particularly in this group.

Registry
clinicaltrials.gov
Start Date
May 2009
End Date
December 2011
Last Updated
11 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Impaired glucose tolerance
  • BMI 16-40 kg/m²

Exclusion Criteria

  • chronic disease
  • therapy with insulin or cortisone

Arms & Interventions

GLP-1

Intervention: GLP-1

Outcomes

Primary Outcomes

Insulin secretion

Time Frame: 1 day

Study Sites (1)

Loading locations...

Similar Trials